Spravato (Esketamine) for Treatment Resistant Depression – An FDA Approved “Breakthrough Therapy”

In March 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Spravato (Esketamine) for use in patients diagnosed with treatment-resistant depression. Spravato is a nasal spray that can only be administered by an approved health care provider, in the physician’s office or clinic, because the main ingredient is a chemical relative of […]




Read More...